HIGHLIGHTS
- who: Gian Luca Rampioni Vinciguerra and colleagues from the Division of Molecular Oncology, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura Carattere Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States, Department of Clinical and have published the Article: CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review, in the Journal: (JOURNAL)
- what: The introduction of CDK-i has drastically changed the clinical approach to HR+ BC and their use is expected to be extended to many other tumor types.
SUMMARY
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.